论文部分内容阅读
美国FDA继2005年批准Nexavar(sorafenib)用于晚期肾细胞癌的治疗后,又于2007-11-19批准其用于治疗不能手术治疗的肝细胞癌患者。Nexavar是一种激酶抑制剂,可作用于在癌细胞中起化学信号传递作用的分子,对供给肿瘤营养的血管的形成和细胞死亡产生调控作用。
After FDA approval of Nexavar (sorafenib) for the treatment of advanced renal cell carcinoma in 2005, the U.S. FDA approved its use in the treatment of unresectable hepatocellular carcinoma from November 2007-19. Nexavar is a kinase inhibitor that acts on molecules that act as chemical signals in cancer cells and regulate the formation of blood vessels that supply tumor nutrition and cell death.